Searched for
RAJEEV NANNAPANENI
NATCO Pharma launches generic blood cancer treatment medicine in USNATCO Pharma has launched generic Pomalidomide capsules in the US. This drug treats blood and bone marrow cancer. It is a generic version o...- Natco Pharma to acquire significant stake in S African firm Adcock IngramIndian pharmaceutical company Natco Pharma is set to acquire significant stakes in South Africa's Adcock Ingram, a 135-year-old firm, in a ...
- Natco Pharma shares dip over 2% after Rs 2,000-crore stake buy in South Africa’s Adcock IngramNatco’s proposed all-cash deal to acquire nearly 36% of AIHL from minority shareholders is aimed at expanding its presence in South Africa,...
- Natco Pharma to buy over 35% in South Africa's Adcock IngramNatco Pharma, based in Hyderabad, is set to acquire a 35.75% stake in Adcock Ingram, South Africa's second-largest drugmaker, for ₹2,000 cr...
- Natco Pharma offers to acquire nearly 36% stake in Adcock Ingram in Rs 2,100-cr dealNatco Pharma has made a firm offer to acquire nearly 36% stake in South African drug firm Adcock Ingram Holdings for up to Rs 2,100 crore. ...
- Natco Pharma acquires 40 million shares in eGenesis IncNatco Pharma's Canadian subsidiary has acquired 40 million shares in eGenesis Inc. for USD 8 million. eGenesis is a biotechnology company d...
- Accumulate Natco Pharma, target price Rs 1116: Geojit Financial ServicesNatco Pharma, incorporated in the year 1981, is a Mid Cap company (having a market cap of Rs 17460.53 crore) operating in pharmaceuticals s...
- Buy Natco Pharma, target price Rs 704: Geojit Financial ServicesNatco Pharma, incorporated in the year 1981, is a Mid Cap company (having a market cap of Rs 10573.71 Crore) operating in Pharmaceuticals s...
- Natco CEO donates Rs 15 cr worth shares to children eye researchRajeev has informed the stock exchanges that he is donating by way of gift through off-market transfer of 1.5 lakh equity shares of Rs 2 ea...
- Natco set for US launch of generic copy of Teva’s drugIf the Hyderabad-based company begins selling the drug now, it may face penal damages on losing the patent battle with Teva.
- Natco examining other drugs to identify compulsory license targetsWe have mostly targeted unaffordable life saving drugs which are either unavailable or in-adequately available at an exorbitant cost. These...
- Natco to enter Russian, S American markets in 2 yearsGeneric drug maker Natco Pharma plans to enter the Russian and South American markets in the next two years.
- Lupin signs agreement with Natco for FosrenolLupin, one of India’s largest pharma companies, on Thursday said it has signed an agreement with mid sized firm Natco to market the generic...
- Natco Pharma soars on drug licensing dealNatco Pharma rose as much as 19 per cent after it struck a licensing and supply deal with US-based Mylan for its generic version of multipl...
- Family jewels: New kids on the blockThey are the new kids on the block. But they aren't quite wet behind the ears. Can they transform traditional small businesses?
Load More
